Marcy Behar Bolster, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rheumatology | 28 | 2024 | 617 | 7.160 |
Why?
|
Bone Density Conservation Agents | 9 | 2024 | 797 | 2.080 |
Why?
|
Osteoporosis | 8 | 2023 | 1606 | 1.920 |
Why?
|
Scleroderma, Systemic | 24 | 2024 | 346 | 1.810 |
Why?
|
Rheumatic Diseases | 9 | 2024 | 659 | 1.730 |
Why?
|
Diphosphonates | 5 | 2024 | 634 | 1.670 |
Why?
|
Arthritis, Rheumatoid | 23 | 2024 | 3780 | 1.580 |
Why?
|
Education, Medical, Graduate | 9 | 2023 | 2422 | 1.220 |
Why?
|
Fellowships and Scholarships | 9 | 2023 | 1134 | 1.160 |
Why?
|
Osteoporotic Fractures | 2 | 2022 | 417 | 0.920 |
Why?
|
Telemedicine | 5 | 2024 | 3110 | 0.870 |
Why?
|
Lung Diseases, Interstitial | 9 | 2024 | 940 | 0.840 |
Why?
|
Antirheumatic Agents | 11 | 2024 | 1381 | 0.840 |
Why?
|
Imidazoles | 2 | 2024 | 1169 | 0.750 |
Why?
|
Fractures, Bone | 2 | 2023 | 2063 | 0.740 |
Why?
|
Curriculum | 13 | 2023 | 3782 | 0.690 |
Why?
|
Muscle Weakness | 1 | 2023 | 413 | 0.680 |
Why?
|
Education, Distance | 1 | 2023 | 260 | 0.670 |
Why?
|
Clinical Competence | 8 | 2023 | 4860 | 0.640 |
Why?
|
Autoimmune Diseases | 6 | 2024 | 2258 | 0.640 |
Why?
|
Glucocorticoids | 6 | 2024 | 2167 | 0.580 |
Why?
|
Hypertension, Pulmonary | 10 | 2018 | 1601 | 0.580 |
Why?
|
Hip Fractures | 1 | 2024 | 997 | 0.520 |
Why?
|
Fractures, Stress | 2 | 2015 | 205 | 0.500 |
Why?
|
Pain Threshold | 6 | 2023 | 606 | 0.490 |
Why?
|
Health Services Needs and Demand | 2 | 2020 | 1407 | 0.480 |
Why?
|
Giant Cell Tumor of Bone | 1 | 2015 | 119 | 0.460 |
Why?
|
Internal Medicine | 2 | 2022 | 1064 | 0.450 |
Why?
|
Orthopedics | 1 | 2022 | 906 | 0.440 |
Why?
|
Education, Medical, Continuing | 1 | 2019 | 829 | 0.430 |
Why?
|
Fibromyalgia | 3 | 2022 | 407 | 0.430 |
Why?
|
Fasciitis | 2 | 2009 | 66 | 0.420 |
Why?
|
Aromatase Inhibitors | 1 | 2016 | 519 | 0.390 |
Why?
|
Internship and Residency | 4 | 2022 | 5956 | 0.370 |
Why?
|
Faculty, Medical | 2 | 2020 | 1226 | 0.370 |
Why?
|
Pandemics | 5 | 2024 | 8749 | 0.370 |
Why?
|
Proton Pump Inhibitors | 1 | 2016 | 552 | 0.360 |
Why?
|
Inpatients | 4 | 2023 | 2569 | 0.340 |
Why?
|
Humans | 97 | 2024 | 768970 | 0.330 |
Why?
|
Preventive Health Services | 1 | 2014 | 570 | 0.330 |
Why?
|
Tibia | 1 | 2015 | 1076 | 0.330 |
Why?
|
Eosinophilia | 2 | 2009 | 556 | 0.320 |
Why?
|
Interprofessional Relations | 1 | 2015 | 997 | 0.320 |
Why?
|
Vertebroplasty | 1 | 2010 | 79 | 0.310 |
Why?
|
Physician Assistants | 3 | 2019 | 190 | 0.310 |
Why?
|
Adrenal Cortex Hormones | 2 | 2016 | 1892 | 0.300 |
Why?
|
Checklist | 1 | 2015 | 841 | 0.300 |
Why?
|
Nurse Practitioners | 3 | 2019 | 271 | 0.290 |
Why?
|
Teaching | 1 | 2015 | 1171 | 0.290 |
Why?
|
Arthralgia | 3 | 2022 | 459 | 0.280 |
Why?
|
Lung Diseases | 4 | 2021 | 1944 | 0.280 |
Why?
|
Hospitalization | 2 | 2024 | 10847 | 0.270 |
Why?
|
Raynaud Disease | 3 | 2014 | 80 | 0.270 |
Why?
|
Needs Assessment | 3 | 2023 | 1143 | 0.270 |
Why?
|
Bone Density | 2 | 2017 | 3574 | 0.260 |
Why?
|
Anticonvulsants | 1 | 2016 | 1924 | 0.260 |
Why?
|
Pulmonary Fibrosis | 6 | 2012 | 506 | 0.260 |
Why?
|
Rheumatoid Factor | 2 | 2020 | 185 | 0.250 |
Why?
|
Consensus | 1 | 2015 | 3214 | 0.250 |
Why?
|
Referral and Consultation | 1 | 2016 | 3628 | 0.210 |
Why?
|
Bone Neoplasms | 1 | 2015 | 2565 | 0.210 |
Why?
|
Myocardial Infarction | 2 | 2022 | 11521 | 0.200 |
Why?
|
Cyclophosphamide | 5 | 2007 | 2227 | 0.200 |
Why?
|
Pain Measurement | 8 | 2023 | 3586 | 0.200 |
Why?
|
Pain | 7 | 2023 | 5100 | 0.190 |
Why?
|
Bronchoalveolar Lavage Fluid | 3 | 2007 | 761 | 0.190 |
Why?
|
Eosinophilia-Myalgia Syndrome | 3 | 1996 | 8 | 0.190 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2003 | 297 | 0.190 |
Why?
|
Joints | 2 | 2007 | 324 | 0.190 |
Why?
|
Glomerulonephritis, IGA | 1 | 2021 | 61 | 0.180 |
Why?
|
Hemosiderosis | 1 | 2021 | 66 | 0.180 |
Why?
|
Accreditation | 2 | 2022 | 477 | 0.180 |
Why?
|
Lovastatin | 1 | 2020 | 115 | 0.170 |
Why?
|
Optics and Photonics | 1 | 2002 | 307 | 0.170 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9264 | 0.170 |
Why?
|
Chronic Periodontitis | 1 | 2021 | 104 | 0.170 |
Why?
|
Evidence-Based Medicine | 2 | 2024 | 3709 | 0.170 |
Why?
|
Prednisone | 2 | 2022 | 1567 | 0.170 |
Why?
|
Proteinuria | 1 | 2003 | 610 | 0.170 |
Why?
|
Acetaminophen | 1 | 2023 | 556 | 0.160 |
Why?
|
Tramadol | 1 | 2020 | 63 | 0.160 |
Why?
|
Tomography | 1 | 2002 | 442 | 0.160 |
Why?
|
Microcirculation | 1 | 2024 | 1281 | 0.160 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 224 | 0.160 |
Why?
|
Personnel Selection | 1 | 2021 | 201 | 0.160 |
Why?
|
Career Mobility | 1 | 2020 | 262 | 0.150 |
Why?
|
Autoantibodies | 2 | 2023 | 2120 | 0.150 |
Why?
|
Myositis | 2 | 2024 | 269 | 0.150 |
Why?
|
Feedback | 1 | 2022 | 799 | 0.150 |
Why?
|
Musculoskeletal System | 1 | 2020 | 188 | 0.150 |
Why?
|
Coronary Circulation | 1 | 2024 | 1617 | 0.150 |
Why?
|
Creatinine | 1 | 2023 | 1917 | 0.150 |
Why?
|
Calcium | 2 | 2023 | 5792 | 0.140 |
Why?
|
Scleroderma, Diffuse | 2 | 2014 | 18 | 0.140 |
Why?
|
Patient Preference | 1 | 2024 | 947 | 0.130 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2002 | 752 | 0.130 |
Why?
|
Secondary Prevention | 1 | 2022 | 1476 | 0.130 |
Why?
|
Pain Perception | 1 | 2018 | 198 | 0.130 |
Why?
|
Program Evaluation | 2 | 2016 | 2508 | 0.130 |
Why?
|
Decision Making | 1 | 2010 | 3953 | 0.130 |
Why?
|
Polymyalgia Rheumatica | 1 | 2016 | 52 | 0.130 |
Why?
|
Female | 45 | 2024 | 397515 | 0.130 |
Why?
|
Catastrophization | 1 | 2019 | 352 | 0.130 |
Why?
|
Systemic Vasculitis | 1 | 2016 | 37 | 0.130 |
Why?
|
Adult | 26 | 2024 | 223851 | 0.130 |
Why?
|
United States | 10 | 2024 | 73186 | 0.120 |
Why?
|
C-Reactive Protein | 3 | 2024 | 3859 | 0.120 |
Why?
|
Teriparatide | 1 | 2017 | 226 | 0.120 |
Why?
|
Scleroderma, Limited | 1 | 2014 | 8 | 0.120 |
Why?
|
Methotrexate | 1 | 2022 | 1723 | 0.120 |
Why?
|
Brassica | 1 | 1994 | 39 | 0.120 |
Why?
|
Sarcoidosis | 2 | 2016 | 535 | 0.120 |
Why?
|
Male | 41 | 2024 | 365203 | 0.120 |
Why?
|
Physicians, Women | 1 | 2020 | 521 | 0.120 |
Why?
|
Middle Aged | 34 | 2024 | 223737 | 0.110 |
Why?
|
Self-Assessment | 1 | 2016 | 400 | 0.110 |
Why?
|
Plant Oils | 1 | 1994 | 199 | 0.110 |
Why?
|
Societies, Medical | 3 | 2024 | 3968 | 0.110 |
Why?
|
Bone Diseases, Metabolic | 1 | 2017 | 411 | 0.110 |
Why?
|
Severity of Illness Index | 10 | 2023 | 15951 | 0.110 |
Why?
|
Aged | 22 | 2024 | 171786 | 0.110 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2020 | 1803 | 0.110 |
Why?
|
Registries | 4 | 2018 | 8384 | 0.110 |
Why?
|
Neoplasms, Connective Tissue | 1 | 2013 | 36 | 0.100 |
Why?
|
Sex Characteristics | 1 | 2023 | 2649 | 0.100 |
Why?
|
Gout | 1 | 2020 | 621 | 0.100 |
Why?
|
Goals | 2 | 2020 | 717 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2010 | 10400 | 0.100 |
Why?
|
Calcinosis | 1 | 2021 | 1479 | 0.100 |
Why?
|
Learning | 1 | 2022 | 1760 | 0.100 |
Why?
|
Certification | 1 | 2015 | 420 | 0.100 |
Why?
|
Giant Cell Arteritis | 1 | 2016 | 307 | 0.090 |
Why?
|
Biopsy, Needle | 2 | 2009 | 1626 | 0.090 |
Why?
|
Scleroderma, Localized | 2 | 2009 | 85 | 0.090 |
Why?
|
Myocardial Ischemia | 1 | 2022 | 2139 | 0.090 |
Why?
|
Bone and Bones | 1 | 2002 | 2590 | 0.090 |
Why?
|
Immunosuppressive Agents | 4 | 2007 | 4207 | 0.090 |
Why?
|
Kidney Failure, Chronic | 1 | 2003 | 2493 | 0.090 |
Why?
|
Risk Factors | 8 | 2022 | 74976 | 0.090 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2018 | 954 | 0.080 |
Why?
|
Vital Capacity | 4 | 2018 | 996 | 0.080 |
Why?
|
Antigens, CD | 1 | 2020 | 4032 | 0.080 |
Why?
|
Respiratory Function Tests | 4 | 2024 | 1694 | 0.080 |
Why?
|
Mesenchymal Stem Cells | 1 | 2020 | 1672 | 0.080 |
Why?
|
Inflammation | 3 | 2024 | 10868 | 0.080 |
Why?
|
Follow-Up Studies | 6 | 2022 | 39394 | 0.080 |
Why?
|
Femoral Fractures | 1 | 2013 | 376 | 0.080 |
Why?
|
Alcohol Drinking | 1 | 2022 | 4045 | 0.080 |
Why?
|
Pregnancy Complications | 1 | 2003 | 2974 | 0.080 |
Why?
|
Imaging, Three-Dimensional | 1 | 2002 | 4076 | 0.080 |
Why?
|
B-Lymphocytes | 1 | 2021 | 4794 | 0.080 |
Why?
|
Treatment Outcome | 12 | 2024 | 65480 | 0.080 |
Why?
|
Fractures, Compression | 1 | 2010 | 132 | 0.070 |
Why?
|
Selection Bias | 1 | 2010 | 360 | 0.070 |
Why?
|
Drug Discovery | 1 | 2016 | 1068 | 0.070 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2016 | 1751 | 0.070 |
Why?
|
History, 20th Century | 1 | 2016 | 2771 | 0.070 |
Why?
|
Vitamins | 1 | 2016 | 1638 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4413 | 0.070 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7460 | 0.070 |
Why?
|
Ultrasonography | 1 | 2020 | 6002 | 0.070 |
Why?
|
Critical Pathways | 1 | 2010 | 476 | 0.070 |
Why?
|
Cohort Studies | 4 | 2022 | 41808 | 0.070 |
Why?
|
Data Collection | 1 | 2015 | 3324 | 0.060 |
Why?
|
Disease Progression | 4 | 2024 | 13674 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3253 | 0.060 |
Why?
|
Mixed Connective Tissue Disease | 1 | 2024 | 32 | 0.060 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 26395 | 0.060 |
Why?
|
Tryptophan | 2 | 1996 | 482 | 0.060 |
Why?
|
Apoptosis | 1 | 2020 | 9527 | 0.060 |
Why?
|
Leukocyte Count | 1 | 2007 | 1609 | 0.050 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2016 | 2171 | 0.050 |
Why?
|
Pulmonary Artery | 1 | 2012 | 1945 | 0.050 |
Why?
|
Spinal Fractures | 1 | 2010 | 712 | 0.050 |
Why?
|
Drug Therapy, Combination | 2 | 2003 | 6320 | 0.050 |
Why?
|
Dietary Supplements | 1 | 2016 | 3443 | 0.050 |
Why?
|
Double-Blind Method | 5 | 2020 | 12467 | 0.050 |
Why?
|
Anesthetics, Local | 1 | 2010 | 1005 | 0.050 |
Why?
|
Hypertension, Renal | 1 | 2003 | 135 | 0.050 |
Why?
|
Eosinophils | 1 | 2007 | 953 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2024 | 59739 | 0.050 |
Why?
|
Pregnancy, High-Risk | 1 | 2003 | 121 | 0.050 |
Why?
|
Sjogren's Syndrome | 1 | 2024 | 241 | 0.050 |
Why?
|
Vitamin D | 1 | 2016 | 3311 | 0.050 |
Why?
|
Ulnar Artery | 1 | 2002 | 15 | 0.050 |
Why?
|
Hemodynamics | 3 | 2016 | 4199 | 0.050 |
Why?
|
Antihypertensive Agents | 2 | 2003 | 2027 | 0.050 |
Why?
|
Absorption | 1 | 2002 | 244 | 0.050 |
Why?
|
Cytokines | 1 | 1997 | 7453 | 0.050 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2007 | 856 | 0.050 |
Why?
|
Peptides, Cyclic | 1 | 2023 | 391 | 0.050 |
Why?
|
Gingival Crevicular Fluid | 1 | 2021 | 96 | 0.050 |
Why?
|
Fetal Death | 1 | 2003 | 434 | 0.050 |
Why?
|
Intubation | 1 | 2020 | 140 | 0.040 |
Why?
|
Respiratory Therapy | 1 | 2020 | 125 | 0.040 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2024 | 346 | 0.040 |
Why?
|
South Carolina | 2 | 2013 | 113 | 0.040 |
Why?
|
Pregnancy Trimester, Second | 1 | 2003 | 736 | 0.040 |
Why?
|
Chickens | 1 | 2002 | 845 | 0.040 |
Why?
|
Prospective Studies | 7 | 2019 | 54962 | 0.040 |
Why?
|
Epoprostenol | 1 | 2000 | 246 | 0.040 |
Why?
|
Troponin T | 1 | 2024 | 787 | 0.040 |
Why?
|
Videoconferencing | 1 | 2021 | 209 | 0.040 |
Why?
|
Electronics | 1 | 2020 | 317 | 0.040 |
Why?
|
Mass Screening | 2 | 2024 | 5457 | 0.040 |
Why?
|
Gout Suppressants | 1 | 2020 | 177 | 0.040 |
Why?
|
Interleukin-1beta | 1 | 2024 | 1026 | 0.040 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2024 | 672 | 0.040 |
Why?
|
Carpal Tunnel Syndrome | 1 | 2001 | 304 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2021 | 1586 | 0.040 |
Why?
|
Lung | 2 | 2014 | 10099 | 0.040 |
Why?
|
Arterial Occlusive Diseases | 1 | 2002 | 746 | 0.040 |
Why?
|
Chemokine CCL3 | 1 | 1997 | 85 | 0.040 |
Why?
|
Chemokine CCL4 | 1 | 1997 | 127 | 0.040 |
Why?
|
Macrophage Inflammatory Proteins | 1 | 1997 | 122 | 0.040 |
Why?
|
Metacarpophalangeal Joint | 1 | 2017 | 82 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2003 | 1321 | 0.030 |
Why?
|
Fingers | 2 | 2002 | 512 | 0.030 |
Why?
|
Ulna | 1 | 2017 | 134 | 0.030 |
Why?
|
Chemokine CCL5 | 1 | 1997 | 214 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15661 | 0.030 |
Why?
|
Gastrointestinal Diseases | 1 | 2005 | 1204 | 0.030 |
Why?
|
Saliva | 1 | 2021 | 854 | 0.030 |
Why?
|
Blood Pressure | 1 | 2012 | 8544 | 0.030 |
Why?
|
Longitudinal Studies | 4 | 2014 | 14794 | 0.030 |
Why?
|
Sex Factors | 2 | 2020 | 10633 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2024 | 1890 | 0.030 |
Why?
|
CREST Syndrome | 1 | 1995 | 6 | 0.030 |
Why?
|
Patient Participation | 1 | 2024 | 1448 | 0.030 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 2014 | 93 | 0.030 |
Why?
|
Neutrophils | 1 | 2007 | 3785 | 0.030 |
Why?
|
Workplace | 1 | 2021 | 873 | 0.030 |
Why?
|
Total Lung Capacity | 2 | 2007 | 148 | 0.030 |
Why?
|
Radius | 1 | 2017 | 443 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2664 | 0.030 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2018 | 497 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2003 | 13021 | 0.030 |
Why?
|
Uric Acid | 1 | 2020 | 806 | 0.030 |
Why?
|
Fatty Acids, Monounsaturated | 1 | 1994 | 190 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 4 | 2024 | 20776 | 0.030 |
Why?
|
Hospitals, University | 2 | 2006 | 570 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2021 | 2744 | 0.030 |
Why?
|
Pre-Eclampsia | 1 | 2003 | 1255 | 0.030 |
Why?
|
Qualitative Research | 1 | 2024 | 3143 | 0.030 |
Why?
|
Fibrosis | 1 | 2020 | 2080 | 0.030 |
Why?
|
Osteomalacia | 1 | 2013 | 60 | 0.030 |
Why?
|
Coronary Vessels | 1 | 2024 | 3124 | 0.030 |
Why?
|
North Carolina | 1 | 2013 | 329 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2020 | 12095 | 0.020 |
Why?
|
Connective Tissue Diseases | 1 | 1995 | 285 | 0.020 |
Why?
|
Bone Nails | 1 | 2013 | 221 | 0.020 |
Why?
|
Paraneoplastic Syndromes | 1 | 2013 | 154 | 0.020 |
Why?
|
Peptides | 1 | 2023 | 4353 | 0.020 |
Why?
|
Leadership | 1 | 2020 | 1396 | 0.020 |
Why?
|
Fracture Fixation, Intramedullary | 1 | 2013 | 160 | 0.020 |
Why?
|
Animals | 4 | 2017 | 169335 | 0.020 |
Why?
|
Age Factors | 1 | 2007 | 18435 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5891 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 3813 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2002 | 3580 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2003 | 11116 | 0.020 |
Why?
|
Quality of Life | 3 | 2007 | 13510 | 0.020 |
Why?
|
Skin | 1 | 2003 | 4506 | 0.020 |
Why?
|
Forecasting | 1 | 2018 | 2945 | 0.020 |
Why?
|
Young Adult | 2 | 2020 | 60131 | 0.020 |
Why?
|
Administration, Oral | 2 | 2007 | 4040 | 0.020 |
Why?
|
Incidence | 1 | 2007 | 21547 | 0.020 |
Why?
|
Educational Measurement | 1 | 2015 | 1260 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9684 | 0.020 |
Why?
|
Syndrome | 1 | 1994 | 3274 | 0.020 |
Why?
|
Collagen | 1 | 1996 | 2646 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9377 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6673 | 0.020 |
Why?
|
Bronchoalveolar Lavage | 1 | 2007 | 131 | 0.020 |
Why?
|
Program Development | 1 | 2013 | 1300 | 0.020 |
Why?
|
Exercise Test | 1 | 2014 | 2187 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8748 | 0.020 |
Why?
|
Motor Activity | 1 | 1996 | 2713 | 0.020 |
Why?
|
Tomography, Spiral Computed | 1 | 2007 | 274 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2017 | 4356 | 0.020 |
Why?
|
Logistic Models | 1 | 2020 | 13318 | 0.020 |
Why?
|
Leukopenia | 1 | 2006 | 212 | 0.020 |
Why?
|
Echocardiography | 1 | 2018 | 5047 | 0.020 |
Why?
|
Depression | 1 | 2005 | 8231 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2002 | 9080 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2024 | 6569 | 0.010 |
Why?
|
Survival Rate | 1 | 2018 | 12873 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2016 | 5151 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2018 | 12562 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 3838 | 0.010 |
Why?
|
Forced Expiratory Volume | 1 | 2007 | 1831 | 0.010 |
Why?
|
Cognition Disorders | 1 | 1996 | 3985 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2013 | 20245 | 0.010 |
Why?
|
Time Factors | 2 | 2018 | 40261 | 0.010 |
Why?
|
Risk Assessment | 1 | 2003 | 24333 | 0.010 |
Why?
|
Risk | 1 | 2014 | 9621 | 0.010 |
Why?
|
Health Status Indicators | 1 | 2007 | 971 | 0.010 |
Why?
|
Sympathectomy | 1 | 2002 | 72 | 0.010 |
Why?
|
Hypesthesia | 1 | 2001 | 106 | 0.010 |
Why?
|
Median Nerve | 1 | 2001 | 133 | 0.010 |
Why?
|
Pregnancy | 1 | 2003 | 30265 | 0.010 |
Why?
|
Paresthesia | 1 | 2001 | 160 | 0.010 |
Why?
|
Ulcer | 1 | 2002 | 203 | 0.010 |
Why?
|
Antibodies, Antinuclear | 1 | 2002 | 342 | 0.010 |
Why?
|
Disability Evaluation | 1 | 2007 | 1839 | 0.010 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2000 | 276 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2007 | 4862 | 0.010 |
Why?
|
Cognition | 1 | 1996 | 7081 | 0.010 |
Why?
|
Saphenous Vein | 1 | 2002 | 519 | 0.010 |
Why?
|
Age of Onset | 1 | 2006 | 3346 | 0.010 |
Why?
|
Cardiac Output | 1 | 2000 | 838 | 0.010 |
Why?
|
Quality Improvement | 1 | 2013 | 3860 | 0.010 |
Why?
|
Regression Analysis | 1 | 2006 | 6346 | 0.010 |
Why?
|
Echocardiography, Doppler | 1 | 2000 | 898 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2000 | 2231 | 0.010 |
Why?
|
Swimming | 1 | 1996 | 209 | 0.010 |
Why?
|
Maze Learning | 1 | 1996 | 481 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1996 | 1553 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2020 | 81903 | 0.010 |
Why?
|
Vascular Surgical Procedures | 1 | 2002 | 1515 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1996 | 1904 | 0.010 |
Why?
|
Health Status | 1 | 2005 | 4095 | 0.010 |
Why?
|
Reaction Time | 1 | 1996 | 2101 | 0.010 |
Why?
|
Analysis of Variance | 1 | 1996 | 6236 | 0.000 |
Why?
|
Mice, Inbred C57BL | 2 | 1996 | 22379 | 0.000 |
Why?
|
Disease Models, Animal | 2 | 1996 | 18354 | 0.000 |
Why?
|
Anticoagulants | 1 | 2002 | 4850 | 0.000 |
Why?
|
Kidney Diseases | 1 | 1997 | 2100 | 0.000 |
Why?
|
Body Weight | 1 | 1996 | 4628 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2013 | 36854 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1996 | 12806 | 0.000 |
Why?
|
Mice | 2 | 1996 | 82072 | 0.000 |
Why?
|
Prognosis | 1 | 1997 | 30046 | 0.000 |
Why?
|